MRK · Merck · Q2 FY2026
Merck elects Paul J. Diaz to its board
Merck announced on Oct 13, 2026 the election of Paul J. Diaz to its board, effective Nov 1, 2026; the Form 8-K filed that day dates the earliest event it reports Oct 9, 2026.
- Published
- Oct 20, 2026
- Event
- Oct 9, 2026
- Quarter ended
- Jun 30, 2026
- Data as of
- Oct 13, 2026
Published becauseA director election was disclosed in a Form 8-K filed Oct 13, 2026, which dates the earliest event it reports Oct 9, 2026; the election takes effect Nov 1, 2026.
The Blockhaven read
Merck elected Paul J. Diaz to its board of directors, effective November 1, 2026, according to a Form 8-K filed October 13, which incorporates the company's press release of the same day. The 8-K gives October 9, 2026 as the date of the earliest event it reports. Mr. Diaz is a managing partner at Cressey & Company and previously led Myriad Genetics and Kindred Healthcare; he also serves on the board of Centene. The board appointed him to both the Audit Committee and the Research Committee, and with his election the board will have 14 members. He will receive compensation as a non-employee director under Merck's director compensation practices, and the filing states that he has no arrangement or understanding with any other person about his election and no related transaction requiring disclosure. He will stand for election by shareholders in May 2027.
Latest reported quarter
13-week quarter · Earnings release filed Aug 4, 2026
Shown for context: the quarter most recently reported when this note was written, on Aug 4, 2026. It is not the subject of this note.
RevenueGAAP
- Latest
- $16.6 billion
- Year ago
- $15.8 billion
- Change
- +5.1% (Up year over year)
Net incomeGAAP
- Latest
- −$1.33 billion
- Year ago
- $4.43 billion
- Change
- −130.2% (Down year over year)
Diluted EPSGAAP
- Latest
- −$0.54
- Year ago
- $1.76
- Change
- −130.7% (Down year over year)
| Measure | Basis | Latest quarter | Year ago | Change |
|---|---|---|---|---|
| Revenue | GAAP | $16.6 billion | $15.8 billion | +5.1% (Up year over year) |
| Net income | GAAP | −$1.33 billion | $4.43 billion | −130.2% (Down year over year) |
| Diluted EPS | GAAP | −$0.54 | $1.76 | −130.7% (Down year over year) |
Revenue growth +5.1% against +4.9% in the prior quarter (year over year, GAAP).
Trend: Deteriorating. GAAP net income weakened; revenue growth was roughly steady.
GAAP unless labelled. Non-GAAP and company-defined measures are labelled.
What changed
- Merck elected Paul J. Diaz to its board of directors, effective November 1, 2026; the board will have 14 members.
- The board appointed Mr. Diaz to the Audit Committee and the Research Committee; the filing states no related-party arrangement requiring disclosure.
Key facts
- Role
- Director as reported
- Action
- Election to the board as reported
- Effective
- November 1, 2026 as reported
- Committees
- Audit; Research as reported
- Board size after election
- 14 members as reported
- Earliest event (8-K cover date)
- October 9, 2026 as reported
Why it matters
A change to the board: Mr. Diaz, a managing partner at the health care investment firm Cressey & Company and a former chief executive of Myriad Genetics and Kindred Healthcare, joins the committees that oversee audit and research.
The election takes effect in Merck's fourth quarter of 2026; the latest reported quarter, Q2 FY2026, ended before it.
What to watch
- The election takes effect on November 1, 2026.
- Mr. Diaz stands for election by shareholders in May 2027, according to Merck's release.
Data and sources
The election and Mr. Diaz's background come from Merck's Form 8-K (Item 5.02) filed Oct 13, 2026, and the press release it incorporates. Quarter figures come from the company's SEC filings and its 8-K earnings release filed Aug 4, 2026. GAAP figures are labelled as such. Blockhaven used no outside forecasts.
Descriptive company facts. Not investment advice, a rating or a recommendation.